Expert opinion on investigational drugs · 2008
Betahistine: what's new on the agenda?
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Barak Nir
Аннотация
BACKGROUND: Betahistine is an orally administered, centrally acting histamine H(1) receptor agonist with partial H(3) antagonistic activity and no H(2)-binding effects. In the past betahistine was clinically studied mainly as a vasodilator for conditions such as cluster headaches, vascular dementia and Meniere's disease, for which it is still used. In recent years, histamine was found to be a key neurotransmitter in the regulation of feeding behavior.
OBJECTIVE: To provide a review of the developmental history and current research interests of betahistine.
METHODS: All reports of betahistine use in animals and humans were retrieved and reviewed.
RESULTS/CONCLUSION: The unique pharmacologic properties of betahistine point to its potential future use as an antiobesity agent.
OBJECTIVE: To provide a review of the developmental history and current research interests of betahistine.
METHODS: All reports of betahistine use in animals and humans were retrieved and reviewed.
RESULTS/CONCLUSION: The unique pharmacologic properties of betahistine point to its potential future use as an antiobesity agent.